Robert A. Reed
No más puestos en curso
Historial de carrera de Robert A. Reed
Antiguos cargos conocidos de Robert A. Reed.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| XENOPORT, INC. | Corporate Officer/Principal | 01/01/2009 | 01/01/2009 |
| Jefferson-Pilot Corp. | Corporate Officer/Principal | - | 05/04/2006 |
| REATA PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | - | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
| ARADIGM CORPORATION | Corporate Officer/Principal | 30/04/2015 | - |
| IMUNON, INC. | Corporate Officer/Principal | 07/12/2009 | - |
Formación de Robert A. Reed.
| The University of North Carolina at Charlotte | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 8 |
Operativa
| Corporate Officer/Principal | 5 |
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorial
| Health Technology | 6 |
| Finance | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| IMUNON, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
| Jefferson-Pilot Corp. | Finance |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Aradigm Corp.
 Aradigm Corp. Pharmaceuticals: MajorHealth Technology Aradigm Corp. was a pharmaceutical company, which was focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. The company was founded in 1991 and was headquartered in Hayward, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
- Bolsa de valores
- Insiders
- Robert A. Reed
- Experiencia
